Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Interest Expenses (2025)

Iovance Biotherapeutics has reported Interest Expenses over the past 3 years, most recently at $13.7 million for Q3 2025.

  • Quarterly results put Interest Expenses at $13.7 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $13.7 million (changed N/A YoY), and the annual figure for FY2014 was -$5660.0, down 101.27%.
  • Interest Expenses for Q3 2025 was $13.7 million at Iovance Biotherapeutics, up from $126924.0 in the prior quarter.
  • Over the last five years, Interest Expenses for IOVA hit a ceiling of $13.7 million in Q3 2025 and a floor of $13.7 million in Q3 2025.